714 results on '"Ducharme, Anique"'
Search Results
52. Proposal for an Ambulatory Heart Failure Management Curriculum for Cardiology Residency Training Programs
53. Evaluation of the right ventricle: Comparison of gated blood-pool single photon electron computed tomography and echocardiography with cardiac magnetic resonance
54. Use of Antioxidants in Patients with Congestive Heart Failure
55. Atrial Electrical Remodeling in Mice With Cardiac‐Specific Overexpression of Angiotensin II Type 1 Receptor
56. Lessons learned from the pandemic that can be translated in the future
57. The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic
58. Outcomes for Women and Men Who Attend a Heart Failure Clinic: Results of a 12-Month Longitudinal Study
59. The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care
60. Severity at Entry to Specialized Heart Failure Clinics: Discrepancies Between Health-Related Quality of Life and Function in Men and Women
61. Description and Assessment of a Common Reference Method for Fluoroscopic and Transesophageal Echocardiographic Localization and Guidance of Mitral Periprosthetic Transcatheter Leak Reduction
62. Learning Curve in Left Ventricular Assist Device Implantation: Low Volumes Do Not Equate Bad Outcomes
63. Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers
64. HERMES: Effects Of Ziltivekimab Versus Placebo On Morbidity And Mortality In Patients With Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation
65. Markers and Correlates of Right Ventricular Function with Computed Tomography, Echocardiography, and Magnetic Resonance
66. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs
67. Reviewing the future of renin-angiotensin system blockade: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation
68. Patient assessment for cardiac resynchronization therapy: Past, present and future of imaging techniques
69. Long COVID-19: A Primer for Cardiovascular Health Professionals, on Behalf of the CCS Rapid Response Team
70. Cardiovascular Care Delivery During the Second Wave of COVID-19 in Canada
71. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy
72. Factors related to time to admission to specialized multidisciplinary clinics in patients with congestive heart failure
73. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials
74. Characteristics of Clinicians Are Associated With Their Beliefs About ICD Deactivation: Insight From the DECIDE-HF Study
75. Transition of CRT clinic to telemedicine during the COVID-19 pandemic: A missed opportunity to optimized patients with heart failure with reduced ejection fraction?
76. Percent Predicted Value for the 6-Minute Walk Test: Using Norm-Referenced Equations to Characterize Severity in Persons With CHF
77. Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: Insights from the Canadian Trial of Atrial Fibrillation (CTAF)
78. Temporal variations in hematocrit values in patients with left ventricular dysfunction: Relationship with cause-specific mortality and morbidity and optimal monitoring – further insights from SOLVD
79. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure – 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies
80. Association of recreational drug consumption, cardiac toxicity and heart transplantation
81. Optimizing Access to Heart Failure Care in Canada During the COVID-19 Pandemic
82. Long-term evolution, secular trends, and risk factors of renal dysfunction following cardiac transplantation
83. Role of echocardiography in acute myocardial infarction
84. GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.
85. Long-Chain Acylcarnitines and Monounsaturated Fatty Acids Discriminate Heart Failure Patients According to Pulmonary Hypertension Status
86. Rhythm control versus rate control for atrial fibrillation and heart failure
87. Inhibiting the renin-angiotensin system with ACE inhibitors or ARBs after MI
88. The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the BRO‐HF retrospective cohort study
89. Lack of Long-Term Benefits of a 6-Month Heart Failure Disease Management Program
90. Effects of Combined Candesartan and ACE Inhibitors on BNP, Markers of Inflammation and Oxidative Stress, and Glucose Regulation in Patients With Symptomatic Heart Failure
91. Heart rate recovery – a potential marker of clinical outcomes in heart failure patients receiving beta-blocker therapy
92. Are there sex-related differences in specialized, multidisciplinary congestive heart failure clinics?
93. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers
94. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction
95. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
96. Do statins prevent heart failure in patients after myocardial infarction?
97. Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril
98. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure
99. Contributors
100. Echocardiography in Acute Coronary Syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.